Ann: XPerience No Rinse Antimicrobial Solution cleared by FDA, page-44

Based on their funded studies, the efficacy of their product is world leading (by not a small margin). So, my view is that once the independent studies corroborate this, we should see product sales skyrocket. If the executive of the company can manage this next phase well, then I see no reason why this share should not do extremely well. Watch out for the progress of the "Complex Patient" study which is being carried out over the next year.

I'm probably more excited about this share than any other in my portfolio and have taken an extremely oversized position in it! I believe the pay-off profile, if management get the roll-out (post covid) done well, should be exceptional.